Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (2016 - 2025)

Fennec Pharmaceuticals' Shares Outstanding history spans 15 years, with the latest figure at $34.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 24.11% year-over-year to $34.2 million, compared with a TTM value of $34.2 million through Dec 2025, up 24.11%, and an annual FY2025 reading of $34.2 million, up 24.11% over the prior year.
  • Shares Outstanding for Q4 2025 was $34.2 million at Fennec Pharmaceuticals, up from $28.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $34.2 million in Q4 2025, with the low at $26.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $27.2 million, with a median of $26.6 million recorded in 2023.
  • Year-over-year, Shares Outstanding skyrocketed 30.69% in 2021 and then rose 0.14% in 2022.
  • Tracing FENC's Shares Outstanding over 5 years: stood at $26.0 million in 2021, then rose by 1.36% to $26.4 million in 2022, then grew by 2.53% to $27.0 million in 2023, then rose by 1.85% to $27.5 million in 2024, then grew by 24.11% to $34.2 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Shares Outstanding are $34.2 million (Q4 2025), $28.1 million (Q3 2025), and $27.7 million (Q2 2025).